Pharmacogenomic Approach to Selecting Antiplatelet Therapy in Patients With Acute Coronary Syndromes: The PHARMCLO Trial.

F. Notarangelo,G. Maglietta,P. Bevilacqua,M. Cereda,P. Merlini,G. Villani,P. Moruzzi,G. Patrizi,G. Malagoli Tagliazucchi,A. Crocamo,A. Guidorossi,F. Pigazzani,Elisa Nicosia,G. Paoli,M. Bianchessi,M. Comelli,C. Caminiti,D. Ardissino

Published 2018 in Journal of the American College of Cardiology

ABSTRACT

No abstract is available for this paper.

PUBLICATION RECORD

Publication year
2018
Venue
Journal of the American College of Cardiology
Publication date
2018-03-11
Fields of study
Medicine
Identifiers
DOI 10.1016/j.jacc.2018.02.029 PMID 29540324
External record
Open on Semantic Scholar
Source metadata
Semantic Scholar, PubMed

CITATION MAP

EXTRACTION MAP

CLAIMS

No claims are published for this paper.

CONCEPTS

No concepts are published for this paper.

REFERENCES

Role of genetic testing in patients undergoing percutaneous coronary intervention
2018cited by this paper
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).
2018cited by this paper
Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
2018cited by this paper
International Expert Consensus on Switching Platelet P2Y12 Receptor–Inhibiting Therapies
2017cited by this paper
Institutional profile: University of Florida Health Personalized Medicine Program.
2017cited by this paper
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
2017cited by this paper
Dual antiplatelet therapy guided by platelet function testing.
2017cited by this paper
Contemporary use of ticagrelor in patients with acute coronary syndrome: insights from Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART).
2016cited by this paper
Physician response to implementation of genotype‐tailored antiplatelet therapy
2016cited by this paper
Clinical Value of CYP2C19 Genetic Testing for Guiding the Antiplatelet Therapy in a Chinese Population
2016cited by this paper
Trends in P2Y12 Inhibitor Use in Patients Referred for Invasive Evaluation of Coronary Artery Disease in Contemporary US Practice.
2016cited by this paper
Rapid and portable, lab-on-chip, point-of-care genotyping for evaluating clopidogrel metabolism.
2015cited by this paper
Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients.
2015cited by this paper
Implementation of pharmacogenetics: The University of Maryland personalized anti‐platelet pharmacogenetics program
2014cited by this paper
2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
2014cited by this paper
Early Clopidogrel Versus Prasugrel Use Among Contemporary STEMI and NSTEMI Patients in the US: Insights From the National Cardiovascular Data Registry
2014cited by this paper
Television Viewing, Computer Use, Time Driving and All‐Cause Mortality: The SUN Cohort
2014cited by this paper
2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
2014cited by this paper
Clinical pharmacogenetics implementation: Approaches, successes, and challenges
2014cited by this paper
Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial.
2013cited by this paper
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
2013cited by this paper
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
2012cited by this paper
A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placem
2012cited by this paper
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
2011cited by this paper
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).
2011cited by this paper
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
2010cited by this paper
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
2009cited by this paper
Genetic determinants of response to clopidogrel and cardiovascular events.
2009cited by this paper
Cytochrome p-450 polymorphisms and response to clopidogrel.
2009cited by this paper
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
2009cited by this paper
GM-CSF autoantibodies in pulmonary alveolar proteinosis.
2007cited by this paper
GM-CSF autoantibodies in pulmonary alveolar proteinosis.
2007cited by this paper
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
2007cited by this paper
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.
2006cited by this paper
Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity
2003cited by this paper
Cibenzoline transforms random re-entry into ordered re-entry in the atria.
1993cited by this paper

CITED BY

Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies.
2026cites this paper
Genetic Determinants of Response to P2Y12 Inhibitors and Clinical Implications.
2026cites this paper
Impact of CYP2C19 point-of-care testing on the clinical outcome in patients receiving personalized clopidogrel therapy: systemic review and meta-analysis
2025cites this paper
Cost-Utility and Budget Impact Analysis of Pharmacogenetic-Guided Antiplatelet Therapy for Acute Coronary Syndrome in Thailand.
2025cites this paper
Implementing CYP2C19 Pharmacogenetic Testing for Personalized Antiplatelet Therapy: Findings From the QPGx-CARES Initiative.
2025cites this paper
Genetic and clinical determinants of MACE and haemorrhage in antiplatelet therapy: insights from pharmacogenomic analysis
2025cites this paper
CYP2C19 and CES1 gene variants affecting clopidogrel metabolism in a South Asian population from Sri Lanka.
2025cites this paper
Pharmacogenomic analysis and clinical annotation of 635 patients.
2025cites this paper
CYP2C19 genotype-guided antiplatelet therapy to prevent thromboembolic events after stent-assisted coil embolization of unruptured intracranial aneurysms: a retrospective cohort study
2025cites this paper
CYP2C19 Genotype and Efficacy of Clopidogrel Initiated Between 24 to 72 Hours for Ischemic Stroke.
2025cites this paper
Osmolality as a predictor of mortality in a community setting of heart failure population with a normal range of serum sodium: a classification and regression tree analysis
2025cites this paper
The Use of Pharmacogenomics in Cardiovascular Care.
2025cites this paper
Type and duration of antithrombotic therapy after treatment of severely calcified lesions
2025cites this paper
Relevance of High Bleeding Risk and Postdischarge Bleeding in Patients Undergoing Percutaneous Coronary Intervention.
2025cites this paper
Optimizing P2Y12 Inhibitor Therapy in Post-PCI Patients Through Genotype-Guided Strategies: A Systematic Review and Meta-Analysis.
2025cites this paper
Pharmacogenomics and its Role in Cardiovascular Diseases: A Narrative Literature Review
2025cites this paper
PharmacoGENEtics in Youth Depression (GENE-YD) Study protocol: a pilot triple-blinded randomised controlled trial using pharmacogenetics to tailor antidepressant treatment in young Australians
2025cites this paper
Long-term safety of oral antiplatelet strategies for patients with acute coronary syndrome undergoing percutaneous coronary intervention.
2025cites this paper
Comparative analysis of point-of-care bedside cyp2c19-testing guided anti-platelet therapy versus conventional therapies for cardiovascular diseases: a systematic review and meta-analysis
2025influential citation
Is CYP2C Haplotype Relevant for Efficacy and Bleeding Risk in Clopidogrel-Treated Patients?
2024cites this paper
International Consensus Statement on Platelet Function and Genetic Testing in Percutaneous Coronary Intervention: 2024 Update.
2024cites this paper
Antiplatelet Strategy for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Systematic Review and Network Meta‐Analysis
2024cites this paper
Genotype-Guided Antiplatelet Therapy: JACC Review Topic of the Week.
2024cites this paper
Impact of CYP2C19 Genotype Status on Clinical Outcomes in Patients with Symptomatic Coronary Artery Disease, Stroke, and Peripheral Arterial Disease: A Systematic Review and Meta-Analysis
2024cites this paper
Cardiovascular Pharmacogenetics: From Discovery of Genetic Association to Clinical Adoption of Derived Test
2024cites this paper
Precision Medicine in Acute Coronary Syndromes
2024influential citation
The Impact of CYP2C19 Genotype on the Platelet Reactivity Index (PRI) among Chronic Coronary Syndromes (CCS) Patients Undergoing Percutaneous Coronary Intervention (PCI): Affectability of Rapid Genetic Testing
2024cites this paper
Genetic Determinants of Response to P2Y12 Inhibitors and Clinical Implications.
2024cites this paper
An update on oral antiplatelet drug interactions with proton pump inhibitors: what are the risks?
2024cites this paper
Stratified medicine for acute and chronic coronary syndromes: A patient-tailored approach.
2024cites this paper
CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart Association
2024cites this paper
Clopidogrel resistance and its relevance: Current concepts
2024cites this paper
Targeted next-generation sequencing panel to investigate antiplatelet adverse reactions in acute coronary syndrome patients undergoing percutaneous coronary intervention with stenting.
2024cites this paper
Genotype-guided prescribing predictors in CYP2C19 intermediate metabolizers receiving percutaneous coronary intervention.
2024cites this paper
Role of Cyp2c19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
2024cites this paper
Review of the Ticagrelor Trials Evidence Base
2024cites this paper
Prognostic Impact of CYP2C19 Genotypes on Long‐Term Clinical Outcomes in Older Patients After Percutaneous Coronary Intervention
2024influential citation
Validation of a New Duplex Real-Time Polymerase Chain Reaction for Chlamydia trachomatis DNA Detection in Ocular Swab Samples
2024cites this paper
Guided vs. conventional anti-platelet therapy for patients with acute coronary syndrome: A meta-analysis of randomized controlled trials
2023cites this paper
Pharmacogenomics of Cardiovascular Drugs for Atherothrombotic, Thromboembolic and Atherosclerotic Risk
2023cites this paper
Patient-Level Exposure to Actionable Pharmacogenomic Medications in a Nationally Representative Insurance Claims Database
2023cites this paper
Navigating the Course of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Review of Guided Approaches
2023cites this paper
Pharmacogenomics in clinical trials: an overview
2023cites this paper
Optimising antithrombotic therapy after ACS and PCI.
2023cites this paper
CYP2C19 loss‐of‐function alleles and use of omeprazole or esomeprazole increase the risk of cardiovascular outcomes in patients using clopidogrel
2023cites this paper
Guided Anti-P2Y12 Therapy in Patients Undergoing PCI: Three Systematic Reviews with Meta-analyses of Randomized Controlled Trials with Homogeneous Design
2023cites this paper
The contribution of genotype-guided selection of P2Y12 inhibitor on prognosis in ACS /CCS patients undergoing percutaneous coronary intervention: a retrospective cohort study
2023cites this paper
Advancements in Percutaneous Coronary Intervention Techniques: A Comprehensive Literature Review of Mixed Studies and Practice Guidelines
2023cites this paper
Sample size determination for adaptive crossover trial in detecting gene-drug interactions
2023cites this paper
Personalised antiplatelet therapies for coronary artery disease: what the future holds.
2023cites this paper
Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium
2023cites this paper
Guided antiplatelet therapy with P2Y12 antagonists in patients undergoing percutaneous coronary intervention: 3 systematic reviews with meta-analyses of randomized controlled trials with homogeneous design
2023cites this paper
How is pharmacogenetics changing clinical trial design for percutaneous coronary intervention?
2023cites this paper
Clinical Impact of CYP2C19 Genotype on Clopidogrel-Based Antiplatelet Therapy After Percutaneous Coronary Intervention.
2023cites this paper
Influence of CYP2C19 genetic variants and smoking on dual antiplatelet efficacy in patients with coronary artery disease
2023cites this paper
Personalized antiplatelet therapy guided by clopidogrel pharmacogenomics in acute ischemic stroke and transient ischemic attack: A prospective, randomized controlled trial
2023cites this paper
Application of Pharmacogenetics for the Use of Antiplatelet and Anticoagulant Drugs
2023cites this paper
Pharmacogenetics of P2Y12 receptor inhibitors
2023cites this paper
Gut microbiota induces high platelet response in patients with ST segment elevation myocardial infarction after ticagrelor treatment
2022cites this paper
High‐Dose Clopidogrel versus Ticagrelor in CYP2C19 intermediate or poor metabolizers after percutaneous coronary intervention: A Meta‐Analysis of Randomized Trials
2022cites this paper
Genotype-Guided Use of P2Y12 Inhibitors: A Review of Current State of the Art
2022cites this paper
Antiplatelet therapy after percutaneous coronary intervention.
2022cites this paper
Genotyping genetic variants of CYP2C19 for precision antiplatelet dosing: state of the art and future perspectives
2022cites this paper
Personalized antiplatelet therapy in patients with coronary artery disease: past, present and future
2022cites this paper
Antiplatelet Therapy and Bleeding Outcomes With CYP2C19 Genotyping
2022influential citation
CYP2C19 genotype and platelet aggregation test-guided dual antiplatelet therapy after off-pump coronary artery bypass grafting: A retrospective cohort study
2022cites this paper
Reduced Mortality With Antiplatelet Therapy Deescalation After Percutaneous Coronary Intervention in Acute Coronary Syndromes: A Meta-Analysis
2022cites this paper
Evaluation of Potential Racial Disparities in CYP2C19‐Guided P2Y12 Inhibitor Prescribing After Percutaneous Coronary Intervention
2022cites this paper
Escalation and De-Escalation of Antiplatelet Therapy after Acute Coronary Syndrome or PCI: Available Evidence and Implications for Practice
2022cites this paper
Comparative evaluation of standard maintenance-dose clopidogrel versus low-dose prasugrel in patients with stable coronary artery disease after percutaneous coronary intervention.
2022cites this paper
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update
2022cites this paper
Evaluation of race and ethnicity disparities in outcome studies of CYP2C19 genotype-guided antiplatelet therapy
2022cites this paper
CYP2C19 polymorphisms and lipoproteins associated with clopidogrel resistance in children with Kawasaki disease in China: A prospective study
2022cites this paper
CYP2C19 loss-of-function alleles predicts clinical outcomes in East Asian patients with acute myocardial infarction undergoing percutaneous coronary intervention and stenting receiving clopidogrel
2022cites this paper
Routine CYP2C19 genotyping to adjust antiplatelet therapy
2022influential citation
Ideal P2Y12 Inhibitor in Acute Coronary Syndrome: A Review and Current Status
2022cites this paper
Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events
2022cites this paper
Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches
2022cites this paper
Influence of Clinically Significant Genes on Antiplatelet Effect of Clopidogrel and Clinical Outcomes in Patients with Acute Coronary Syndrome and Atrial Fibrillation
2022cites this paper
Naoxintong capsule limits myocardial infarct expansion by inhibiting platelet activation through the ERK5 pathway.
2022cites this paper
Does individualized guided selection of antiplatelet therapy improve outcomes after percutaneous coronary intervention? A systematic review and meta-analysis
2022cites this paper
Effect of genotype guided oral P2Y12 inhibitor selection after percutaneous coronary intervention: A systematic review and meta-analysis of randomized clinical trials.
2022cites this paper
Antiplatelet therapy in cardiovascular disease: Current status and future directions
2022cites this paper
Artificial-Intelligence-Assisted Discovery of Genetic Factors for Precision Medicine of Antiplatelet Therapy in Diabetic Peripheral Artery Disease
2022cites this paper
Genotype-Guided Antiplatelet Therapy Versus Standard Therapy for Patients with Coronary Artery Disease: An Updated Systematic Review and Meta-Analysis.
2022cites this paper
CYP2C19 Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings
2022cites this paper
Pharmacogenetic interventions to improve outcomes in patients with multimorbidity or prescribed polypharmacy: a systematic review
2022cites this paper
Monitoring antiplatelet therapy: where are we now?
2022cites this paper
Genotype-Guided P2Y12 Inhibitor Therapy After Percutaneous Coronary Intervention: A Bayesian Analysis
2021cites this paper
A Propensity-Matched Nested Case-Control Study of Acute Coronary Syndrome Patients Genotyped for CYP2C19
2021cites this paper
Impact of Implementing CYP2C19 Genotype-Guided Antiplatelet Therapy on P2Y12 Inhibitor Selection and Clinical Outcomes in Acute Coronary Syndrome Patients After Percutaneous Coronary Intervention: A Real-World Study in China
2021cites this paper
Patient-tailored antithrombotic therapy following percutaneous coronary intervention
2021influential citation
P2Y12 inhibitors in neuroendovascular surgery: An opportunity for precision medicine
2021cites this paper
The Role of Genetic Polymorphism and Other Factors on Clopidogrel Resistance (CR) in an Asian Population with Coronary Heart Disease (CHD)
2021cites this paper
Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
2021cites this paper
Precision Phenomapping of Acute Coronary Syndromes to Improve Patient Outcomes
2021cites this paper
Pharmacogenetics to guide cardiovascular drug therapy
2021cites this paper
Acute coronary syndromes and percutaneous coronary intervention—current recommendations for dual antiplatelet therapy. Are guidelines reflecting the data?
2021cites this paper
Peripheral blood DNA and RNA biomarkers of cardiovascular disease in clinical practice
2021cites this paper
Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations
2021cites this paper